Sleep, Fatigue, and Functional Health in Psychotic Patients

Table 1

Demographic and clinical characteristics for all participant, and scores on the PSQI, ChFS FSI, and SF36 scales.

Variables	Mean ± SD (range)
Age	39.33 ± 12.08 (19–67)
Sex	M = 75, F = 18
Length of illness (in years)	16.64 ± 11.18
Chlorpromazine equivalent dose	913.51 ± 600.19 (66.5–2496)
ChFS^1 mental fatigue score; (max = 12)	5.02 ± 2.29 (0–12)
ChFS^2 physical fatigue score; (max = 21)	9.14 ± 3.81 (0–19)
FSI^2 severity composite	4.30 ± 2.31 (0–9.50)
FSI^2 perceived interference	3.54 ± 2.50 (0–8.86)
FSI^2 days	3.55 ± 2.65 (0–7)
FSI^2 percent	3.54 ± 2.91 (0–10)
PSQI^3 daily disturbances factor	2.35 ± 1.38 (0–5)
PSQI^3 sleep efficiency factor	1.17 ± 1.59 (0–6)
PSQI^3 perceived sleep quality factor	3.10 ± 2.07 (0–8)
PSQI^3 total score	6.62 ± 3.80 (0–17)
SF36^4 mental health	57.22 ± 20.44 (3–100)
SF36^4 physical health	61.14 ± 21.26 (12–98)
SF36^4 total score	59.93 ± 20.45 (14–99)

1The Chalder Fatigue Scale [18], ²The Fatigue Scale Inventory 1998 [19], ³the Pittsburgh Sleep Quality Index [20], and ⁴SF36 Health Survey [35].